Pharmamarketeer

AstraZeneca announces update on phase III NEPTUNE trial of Imfinzi in combo with tremelimumab in stage IV NSCLC

AstraZeneca announced final overall survival (OS) results from the phase III NEPTUNE trial, a randomised, open─label, multi─centre, global trial of Imfinzi (durvalumab) in combination with tremelimumab, an anti─CTLA4

Medhc-fases-banner
Advertentie(s)